IL210381A0 - Il-29 polypeptide conjugate - Google Patents

Il-29 polypeptide conjugate

Info

Publication number
IL210381A0
IL210381A0 IL210381A IL21038110A IL210381A0 IL 210381 A0 IL210381 A0 IL 210381A0 IL 210381 A IL210381 A IL 210381A IL 21038110 A IL21038110 A IL 21038110A IL 210381 A0 IL210381 A0 IL 210381A0
Authority
IL
Israel
Prior art keywords
amino acid
seq
cysteine
acid residues
correspond
Prior art date
Application number
IL210381A
Other languages
English (en)
Original Assignee
Zymogenetics Llc
Bristol Myers Squibb Co
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Llc, Bristol Myers Squibb Co, Zymogenetics Inc filed Critical Zymogenetics Llc
Publication of IL210381A0 publication Critical patent/IL210381A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL210381A 2003-08-07 2010-12-30 Il-29 polypeptide conjugate IL210381A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49319403P 2003-08-07 2003-08-07
US55184104P 2004-03-10 2004-03-10
US55914204P 2004-04-02 2004-04-02
PCT/US2004/025864 WO2005023862A2 (en) 2003-08-07 2004-08-09 Homogeneous preparations of il-28 and il-29

Publications (1)

Publication Number Publication Date
IL210381A0 true IL210381A0 (en) 2011-03-31

Family

ID=34279787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210381A IL210381A0 (en) 2003-08-07 2010-12-30 Il-29 polypeptide conjugate

Country Status (15)

Country Link
US (38) US7157559B2 (enExample)
EP (4) EP2251353B1 (enExample)
JP (2) JP4808157B2 (enExample)
CN (1) CN1910200A (enExample)
AT (1) ATE388963T1 (enExample)
AU (1) AU2004270652B2 (enExample)
CA (1) CA2534907C (enExample)
CY (1) CY1114030T1 (enExample)
DE (1) DE602004012424T2 (enExample)
DK (2) DK1668031T3 (enExample)
ES (2) ES2303132T3 (enExample)
IL (1) IL210381A0 (enExample)
PL (1) PL2251353T3 (enExample)
PT (1) PT2251353E (enExample)
WO (1) WO2005023862A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP2132984A3 (en) 2000-06-30 2010-11-03 ZymoGenetics, L.L.C. Interferon-like protein ZCYTO21
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
WO2004037995A2 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US20050244423A1 (en) * 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
ES2579758T3 (es) * 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP4987001B2 (ja) * 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
AU2006269908A1 (en) * 2005-07-20 2007-01-25 Bristol-Myers Squibb Company IL28 and IL29 truncated cysteine mutants and antiviral methods of using same
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
RU2562108C2 (ru) * 2007-09-20 2015-09-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Органайзейшн Новые цитокины птиц и кодирующие их генетические последовательности
US8354125B2 (en) 2007-10-27 2013-01-15 Grant Gallagher Ex-vivo treatment of peripheral blood leukocytes with IFN-λ
WO2009071696A2 (en) 2007-12-07 2009-06-11 Zymogenetics, Inc. Humanized antibody molecules specific for il-31
CN105535961A (zh) 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
MX2011002250A (es) * 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
US8363580B2 (en) * 2009-03-31 2013-01-29 Rosemount Inc. Disparate radios in a wireless mesh network
EP2362332A1 (en) 2010-02-26 2011-08-31 Seremfor, S.L.U. Method and system of auto checking personal protective equipment, systems and technical work instructions as regards labour risk prevention
WO2011143608A1 (en) * 2010-05-13 2011-11-17 Avi Biopharma, Inc. Antisense modulation of interleukins 17 and 23 signaling
WO2012065755A1 (en) * 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
CN102559737A (zh) * 2011-12-13 2012-07-11 江南大学 一种人白细胞介素29的变异体及其制备方法
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CA2891974A1 (en) * 2012-11-21 2014-05-30 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
US9464321B2 (en) * 2013-03-15 2016-10-11 Medical Diagnostic Laboratories, Llc Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans
US10246501B2 (en) 2014-01-08 2019-04-02 Prosit Sole Biotechnology (Beijing) Co, Ltd Fusion polypeptides and methods of use
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104672318A (zh) * 2014-12-17 2015-06-03 江南大学 一种肽链第43位赖氨酸定点突变为亮氨酸的人白介素-29变异体
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN105037523B (zh) * 2015-06-25 2019-02-19 北京三元基因药业股份有限公司 干扰素突变体及其聚乙二醇衍生物
JP7187315B2 (ja) 2015-11-04 2022-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッド デルタ型肝炎ウイルス感染の処置
ES2968038T3 (es) 2015-12-23 2024-05-06 Univ Johns Hopkins Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas
SMT202100335T1 (it) 2016-02-19 2021-07-12 Eiger Biopharmaceuticals Inc Trattamento dell'infezione da virus dell'epatite con interferone lambda
CN106047806B (zh) * 2016-08-19 2019-07-16 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的外周血细胞培养基
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
ES3015227T3 (en) * 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107630086B (zh) * 2017-11-13 2020-11-03 吉林大学 一种与hbv感染相关的snp分子标记及其应用
CN108070647B (zh) * 2017-12-25 2021-06-01 吉林大学 与hbv感染相关的基因单体型及其应用
CN108570459B (zh) * 2018-04-10 2022-10-04 南京农业大学 一种高效发酵生产重组细菌漆酶的方法
CA3169594A1 (en) * 2020-02-06 2021-08-12 Eiger Biopharmaceuticals, Inc. Treatment of coronavirus infection with interferon lambda
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
TW202207950A (zh) 2020-06-22 2022-03-01 美商詹森藥物公司 治療d型肝炎病毒感染之組合物及方法
CN115385998B (zh) * 2021-04-13 2025-08-05 杭州先为达生物科技股份有限公司 稳定的iii型干扰素蛋白及其融合蛋白
CN116219078B (zh) * 2023-05-08 2023-07-11 上海惠盾因泰生物科技有限公司 一种il-29生物学活性测定方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485332A (en) * 1892-11-01 Wagon-brake
PH21848A (en) 1980-01-08 1988-03-17 Biogen Nv Dna sequences and recombinant dna molecules
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
CZ221496A3 (en) 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1997017450A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US6001597A (en) 1995-11-09 1999-12-14 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1062332A2 (en) 1998-03-09 2000-12-27 Schering Corporation Human receptor proteins; related reagents and methods
AU3891600A (en) 1999-03-18 2000-10-04 Zymogenetics Inc. Murine interferon-alpha named also zcyto13
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6376585B1 (en) 2000-06-26 2002-04-23 Apex Advanced Technologies, Llc Binder system and method for particulate material with debind rate control additive
AU2001271589A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
EP2132984A3 (en) 2000-06-30 2010-11-03 ZymoGenetics, L.L.C. Interferon-like protein ZCYTO21
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
ATE445701T1 (de) 2000-11-28 2009-10-15 Zymogenetics L L C Zytokine rezeptor zcytor19
JP2002308030A (ja) * 2001-04-16 2002-10-23 Yazaki Corp 車両用周辺監視装置
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EP1942187B1 (en) * 2001-04-20 2010-09-22 ZymoGenetics, L.L.C. Cytokine protein family
WO2002092762A2 (en) 2001-05-10 2002-11-21 Immunex Corporation Cytokine polypeptides
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
AU2003215136A1 (en) * 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
CN101676728A (zh) 2002-04-19 2010-03-24 津莫吉尼蒂克斯公司 细胞因子受体
WO2004037995A2 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US7259969B2 (en) * 2003-02-26 2007-08-21 Wavezero, Inc. Methods and devices for connecting and grounding an EMI shield to a printed circuit board
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
US7208541B2 (en) * 2003-08-22 2007-04-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesive
US20050244423A1 (en) * 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
JP4468734B2 (ja) * 2004-04-27 2010-05-26 オリンパス株式会社 映像信号処理装置と映像信号処理プログラム
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il－29工程菌
JP4987001B2 (ja) 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
AU2006269908A1 (en) * 2005-07-20 2007-01-25 Bristol-Myers Squibb Company IL28 and IL29 truncated cysteine mutants and antiviral methods of using same
DE102005000107B4 (de) * 2005-08-25 2014-03-13 Hilti Aktiengesellschaft Pneumatisch betriebenes Setzgerät
CA2625208A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
AU2009255994B2 (en) 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C

Also Published As

Publication number Publication date
US7608428B2 (en) 2009-10-27
CA2534907A1 (en) 2005-03-17
AU2004270652B2 (en) 2010-06-03
US20100104531A1 (en) 2010-04-29
AU2004270652A1 (en) 2005-03-17
US20070055052A1 (en) 2007-03-08
US7495077B2 (en) 2009-02-24
US7608427B2 (en) 2009-10-27
PT2251353E (pt) 2013-05-07
US20130089517A1 (en) 2013-04-11
US20070048274A1 (en) 2007-03-01
US20070048275A1 (en) 2007-03-01
EP2251353A1 (en) 2010-11-17
US7495078B2 (en) 2009-02-24
US7157559B2 (en) 2007-01-02
EP2251352A1 (en) 2010-11-17
US7544779B2 (en) 2009-06-09
JP2011200252A (ja) 2011-10-13
US20070043210A1 (en) 2007-02-22
US20070154446A1 (en) 2007-07-05
US7582450B2 (en) 2009-09-01
DE602004012424T2 (de) 2009-04-30
US20070059313A1 (en) 2007-03-15
US7629149B2 (en) 2009-12-08
US7468423B2 (en) 2008-12-23
CY1114030T1 (el) 2016-07-27
JP2007528719A (ja) 2007-10-18
ATE388963T1 (de) 2008-03-15
US8343476B2 (en) 2013-01-01
US7662590B2 (en) 2010-02-16
US20070048277A1 (en) 2007-03-01
CA2534907C (en) 2014-04-29
US20140178333A1 (en) 2014-06-26
DK2251353T3 (da) 2013-06-03
US20070054377A1 (en) 2007-03-08
US20070048276A1 (en) 2007-03-01
ES2405209T3 (es) 2013-05-30
US20170209542A1 (en) 2017-07-27
WO2005023862A9 (en) 2006-06-08
WO2005023862A2 (en) 2005-03-17
US20070066810A1 (en) 2007-03-22
EP1927600A1 (en) 2008-06-04
US7595174B2 (en) 2009-09-29
US9499598B2 (en) 2016-11-22
US20070053875A1 (en) 2007-03-08
US20070048843A1 (en) 2007-03-01
US20050037012A1 (en) 2005-02-17
US7588918B2 (en) 2009-09-15
US8734776B2 (en) 2014-05-27
EP1668031B1 (en) 2008-03-12
US20070059804A1 (en) 2007-03-15
US7514536B2 (en) 2009-04-07
US20070172923A1 (en) 2007-07-26
US7588919B2 (en) 2009-09-15
US7629148B2 (en) 2009-12-08
US20070049737A1 (en) 2007-03-01
US20070041936A1 (en) 2007-02-22
US20070042471A1 (en) 2007-02-22
US20070054375A1 (en) 2007-03-08
US20070054374A1 (en) 2007-03-08
US7479542B2 (en) 2009-01-20
US7485701B2 (en) 2009-02-03
US20070054376A1 (en) 2007-03-08
WO2005023862A3 (en) 2005-06-16
US20070117967A1 (en) 2007-05-24
US20070065406A1 (en) 2007-03-22
DK1668031T3 (da) 2008-06-30
EP2251353B1 (en) 2013-03-06
US7517961B2 (en) 2009-04-14
US7727518B2 (en) 2010-06-01
US20120004161A1 (en) 2012-01-05
ES2303132T3 (es) 2008-08-01
US20070042469A1 (en) 2007-02-22
US20070041975A1 (en) 2007-02-22
US7495079B2 (en) 2009-02-24
US7662589B2 (en) 2010-02-16
US20080279816A1 (en) 2008-11-13
US20070055053A1 (en) 2007-03-08
US20070048844A1 (en) 2007-03-01
HK1150618A1 (en) 2012-01-06
JP4808157B2 (ja) 2011-11-02
US7485702B2 (en) 2009-02-03
PL2251353T3 (pl) 2013-08-30
DE602004012424D1 (de) 2008-04-24
US20070073044A1 (en) 2007-03-29
US20070055051A1 (en) 2007-03-08
US20070042470A1 (en) 2007-02-22
CN1910200A (zh) 2007-02-07
US20070166282A1 (en) 2007-07-19
US7638305B2 (en) 2009-12-29
US20070055054A1 (en) 2007-03-08
EP1668031A2 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
IL210381A0 (en) Il-29 polypeptide conjugate
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
WO1995025749A3 (en) Eating suppressant peptides
CA2423887A1 (en) Recombinant terminal deoxynucleotidyl transferase with improved functionality
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
PE20000560A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
IL102346A0 (en) Cysteine depleted il-6 muteins
SG63621A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
AU9026691A (en) New human recombinant gamma interferon
AU2003264535A1 (en) Tumor antigen protein and utilization thereof
ATE353913T1 (de) Neue collectine
AU637589B2 (en) Ancrod proteins, their production and use
WO2007002233A3 (en) Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
DE60325227D1 (enExample)
AU2003274173A1 (en) Peptides and recombinant proteins mimicking interferons
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
WO2003018806A1 (fr) Nouveau gene humain bmcc1
DE60041075D1 (de) Antigene modifikation von polypeptiden
MX9702475A (es) Analogos del factor de crecimiento acido de fibroblasto que tienen estabilidad y acticidad biologica mejoradas.